J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 M e d i c a l u s e s
2 R e f e r e n c e s
3 E x t e r n a l l i n k s
T o g g l e t h e t a b l e o f c o n t e n t s
D a p a g l i f l o z i n / s a x a g l i p t i n
A d d l a n g u a g e s
A d d l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Dapagliflozin/saxagliptin , sold under the brand name Qtern , is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes .[2] [3] dapagliflozin and saxagliptin .[2] [3] [2] [3]
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3] [4]
Medical uses [ edit ]
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes .[2]
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
to improve glycemic control when metformin with or without sulphonylurea (SU ) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.[3]
when already being treated with saxagliptin and dapagliflozin.[3]
References [ edit ]
^ a b c d e f g h "Qtern EPAR" . European Medicines Agency (EMA). Retrieved 14 July 2020 .
^ "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)" . U.S. Food and Drug Administration (FDA) . 10 October 2018. Retrieved 14 July 2020 .
External links [ edit ]
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Dapagliflozin/saxagliptin&oldid=1228240288 " C a t e g o r i e s : ● A d a m a n t a n e s ● D r u g s d e v e l o p e d b y A s t r a Z e n e c a ● C a r b o x a m i d e s ● C h l o r o a r e n e s ● C o m b i n a t i o n d i a b e t e s d r u g s ● D i p e p t i d y l p e p t i d a s e - 4 i n h i b i t o r s ● G l u c o s i d e s ● N i t r i l e s ● N i t r o g e n h e t e r o c y c l e s ● P h e n o l e t h e r s ● S G L T 2 i n h i b i t o r s ● T e r t i a r y a l c o h o l s ● G a s t r o i n t e s t i n a l s y s t e m d r u g s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n m a t c h e s W i k i d a t a ● A r t i c l e s l a c k i n g r e l i a b l e r e f e r e n c e s f r o m J u l y 2 0 2 0 ● A l l a r t i c l e s l a c k i n g r e l i a b l e r e f e r e n c e s ● U s e d m y d a t e s f r o m J u l y 2 0 2 0 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s w i t h o u t U N I I s o u r c e ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a c o m b i n a t i o n o f c h e m i c a l s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 1 0 J u n e 2 0 2 4 , a t 0 5 : 2 3 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
